NCT07671937Recruiting
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 2748 (estimated)
- First submitted
- 22 Jun 2026
- Start date
- 2 Oct 2026
- Primary completion date
- Jul 2030
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Pancreatic cancer, Ovarian cancer
- NCT number
- NCT07671937
What you commit to
- Study type: Interventional
- Planned participants: 2748
- From 2 Oct 2026 to the primary completion date, Jul 2030
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Exclusion criteria - Patients:
- Individuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish.
Other
- Exclusion criteria - Clinician:
- Clinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.
Who the study is looking for
- Inclusions Criteria- Patients:
- aged 18 years or older;
- with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis;
- intention to be treated at a participating institution;
- with verbal fluency in English or Spanish; and
- scheduled to be discussed at MDTB.
- Inclusion criteria - Clinicians:
- All clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation.
Criteria the registry did not label
- Inclusion/Exclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
| University of California Los Angeles (UCLA). Coordinator of this site? Confirm its status | Los Angeles | United States | Not yet recruiting |
| University of Oklahoma (OU) Health Campus Coordinator of this site? Confirm its status | Oklahoma City | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.